VIVES is a multi-sector fund that invests in projects with a positive societal impact
Eligo Bioscience is the world leader in microbiome in vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immunoinflammation...
Promethera Biosciences’ mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide...
Axinesis is a spin-off of the Université Catholique de Louvain (BE), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies dedicated...
Philippe Mengal, past CEO Greenwatt:
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Eric de La Fortelle, Venture Partner at Seventure Partners:
"The tech transfer organization SOPARTEC and the associated fund VIVES played a key role in the initial structuring and the foundation of...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to